For the hundreds of thousands of men who undergo radical prostatectomy each year, one question looms over every postoperative ...
Hosted on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
For men diagnosed with high-risk prostate cancer, surgery is often part of the treatment plan, but nearly half of all patients who undergo radical prostatectomy for high-risk disease will see their ...
A small, early clinical trial led by the Icahn School of Medicine at Mount Sinai and collaborators has shown that directly injecting an immune-activating compound into prostate tumors before surgery ...
Newswise — BOSTON, May 31, 2026 – High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) ...
High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results